Tudor Investment Corp ET AL Has $6.75 Million Position in Schrodinger, Inc. $SDGR
Tudor Investment Corp ET AL significantly increased its stake in Schrodinger, Inc. (NASDAQ:SDGR) by 2,530.6% during the third quarter, now owning 336,379 shares valued at approximately $6.75 million. Despite beating quarterly earnings and revenue expectations, Schrodinger remains unprofitable with negative margins, holding an average analyst rating of "Hold" and a price target of $21.13. Recent insider selling has occurred, but institutional investors hold a substantial 79.05% of the stock.
How this was made

The 30-second read
Why it matters
The surge in institutional ownership could support short-term price stability or upward movement. However, the company's profitability issues and insider selling introduce downside risks. The market's reaction will depend on broader biotech sector trends and macroeconomic factors.
Market read
The news indicates notable institutional activity in a biotech firm with mixed fundamentals, suggesting cautious optimism with inherent risks.
What to watch
Market-wide biotech corrections or macroeconomic factors could overshadow company-specific news, leading to unexpected price movements.
Background
Schrodinger, Inc. specializes in computational drug discovery and life sciences. The company recently reported quarterly earnings exceeding expectations but remains unprofitable, with negative margins. Institutional investors, notably Tudor Investment, increased their holdings significantly, indicating confidence or strategic positioning.
Ticker impact
Significant insider activity and quarterly earnings report.
Potential short-term price stabilization or slight upward movement due to increased institutional interest, but long-term outlook remains cautious.
The large increase in institutional holdings signals confidence, but persistent unprofitability and insider selling introduce uncertainty.
Market effects
Potential positive sentiment for biotech and life sciences sectors due to increased institutional interest.
Limited regional impact; focused on US-based company.
Moderate; reflects institutional activity which can influence global biotech investment trends.
Counterpoint
The large insider selling and persistent unprofitability could signal underlying issues, suggesting a potential decline despite institutional buying.
Key entities
- CompanySchrodinger, Inc.
A biotech and computational drug discovery firm.
- Institutional InvestorTudor Investment Corp ET AL
An investment firm increasing its stake in SDGR.




